Baxter International Inc. (NYSE:BAX) Shares Bought by Jump Financial LLC

Jump Financial LLC increased its holdings in shares of Baxter International Inc. (NYSE:BAX - Free Report) by 1,078.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 139,028 shares of the medical instruments supplier's stock after purchasing an additional 127,228 shares during the period. Jump Financial LLC's holdings in Baxter International were worth $4,054,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Anchor Investment Management LLC increased its stake in Baxter International by 79.2% in the 4th quarter. Anchor Investment Management LLC now owns 20,463 shares of the medical instruments supplier's stock valued at $597,000 after buying an additional 9,043 shares during the period. Sterling Capital Management LLC lifted its stake in shares of Baxter International by 55.2% in the fourth quarter. Sterling Capital Management LLC now owns 30,264 shares of the medical instruments supplier's stock valued at $882,000 after purchasing an additional 10,768 shares during the period. Jaffetilchin Investment Partners LLC boosted its position in Baxter International by 115,259.6% during the fourth quarter. Jaffetilchin Investment Partners LLC now owns 65,755 shares of the medical instruments supplier's stock worth $1,917,000 after purchasing an additional 65,698 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Baxter International by 40.4% during the fourth quarter. Russell Investments Group Ltd. now owns 1,745,709 shares of the medical instruments supplier's stock valued at $50,904,000 after acquiring an additional 502,370 shares during the last quarter. Finally, Oarsman Capital Inc. acquired a new position in Baxter International in the 4th quarter valued at about $157,000. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Baxter International Stock Up 2.0 %

BAX traded up $0.56 during trading on Tuesday, hitting $29.10. The company had a trading volume of 423,092 shares, compared to its average volume of 4,528,769. The business has a 50-day moving average of $32.45 and a 200-day moving average of $32.56. The company has a market cap of $14.93 billion, a PE ratio of -22.73, a P/E/G ratio of 0.93 and a beta of 0.64. Baxter International Inc. has a 1-year low of $26.25 and a 1-year high of $41.18. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.43 and a quick ratio of 1.09.

Baxter International (NYSE:BAX - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 EPS for the quarter, topping analysts' consensus estimates of $0.52 by $0.06. The company had revenue of $2.75 billion for the quarter, compared to the consensus estimate of $2.67 billion. Baxter International had a positive return on equity of 16.67% and a negative net margin of 5.05%. As a group, analysts forecast that Baxter International Inc. will post 2.48 earnings per share for the current year.

Baxter International Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 1st. Investors of record on Friday, February 28th were given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.34%. The ex-dividend date of this dividend was Friday, February 28th. Baxter International's dividend payout ratio is presently -53.13%.

Analyst Upgrades and Downgrades

BAX has been the subject of several analyst reports. The Goldman Sachs Group began coverage on Baxter International in a report on Wednesday, February 26th. They issued a "buy" rating and a $42.00 price target for the company. Argus raised shares of Baxter International from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. JPMorgan Chase & Co. dropped their price target on Baxter International from $38.00 to $36.00 and set a "neutral" rating for the company in a research note on Friday, February 21st. Finally, Barclays increased their target price on shares of Baxter International from $39.00 to $41.00 and gave the stock an "overweight" rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, Baxter International has a consensus rating of "Hold" and a consensus price target of $38.56.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.